Related Experiment Video
Updated: May 31, 2025
LC-MS Analysis of Human Platelets as a Platform for Studying Mitochondrial Metabolism
Published on: April 4, 2016
MITOCDNB DECREASES PLATELET ACTIVATION THROUGH ITS SELECTIVE ACTION ON MITOCHONDRIAL THIOREDOXIN REDUCTASE
Diego Méndez1, Francisca Tellería1, Marcelo Alarcón1
1Thrombosis and Healthy Aging Research Center, MIBI: Interdisciplinary Group on Mitochondrial Targeting and Bioenergetics, Medical Technology School, Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Universidad de Talca, Talca, Chile.
Abstract:
Platelet inhibition is a fundamental objective to prevent and treat thrombus formation. Platelet activation depends on mitochondrial function. This study aims to identify a new mitochondria-targeting compound with antiplatelet activity at safe concentrations in vitro. Cytotoxicity and viability tests were performed on human platelets from volunteer donors, together with experiments on aggregation, platelet activation, mitochondrial function, mitochondrial respiration, and thioredoxin reductase 2 (TrxR2) enzymatic activity in isolated platelet mitochondria. The compound MitoCDNB, corresponding to the molecule 5-chloro-2,4-dinitrophenylamino linked with triphenylphosphonium cation (TPP+) by a butyl chain and methanesulfonate as the counterion, was evaluated. MitoCDNB demonstrates potent, high mitochondria-selective antiplatelet effects that provide a novel approach to platelet inhibition with potentially minimized systemic risks. Here, we describe the first compound that inhibits platelet activation by decreasing TrxR2 enzymatic activity and collagen-stimulated maximal mitochondrial respiration, preventing aggregation and platelet activation. These results can be used to develop new antiplatelet drugs targeting mitochondria.
Insights
Researchers identified MitoCDNB, a novel mitochondria-targeting compound, as a potent platelet inhibitor. This new agent effectively reduces platelet activation and aggregation, offering a promising approach for preventing thrombus formation with potentially fewer side effects.
Area of Science:
- Biochemistry
- Pharmacology
- Mitochondrial Medicine
Background:
- Platelet inhibition is crucial for managing thrombosis.
- Platelet activation is intrinsically linked to mitochondrial function.
- There is a need for novel antiplatelet agents with targeted mechanisms.
Purpose of the Study:
- To discover and characterize a new mitochondria-targeting compound with antiplatelet properties.
- To evaluate the safety and efficacy of the compound in vitro.
- To elucidate the mechanism of action of the novel compound on platelet function.
Main Methods:
- Cytotoxicity and viability assays on human platelets.
- Assessment of platelet aggregation and activation.
- Analysis of mitochondrial function, respiration, and thioredoxin reductase 2 (TrxR2) activity.
- Evaluation of the compound MitoCDNB (5-chloro-2,4-dinitrophenylamino-TPP+).
Main Results:
- MitoCDNB exhibited potent, mitochondria-selective antiplatelet effects.
- The compound inhibited TrxR2 enzymatic activity and collagen-stimulated mitochondrial respiration.
- MitoCDNB successfully prevented platelet aggregation and activation in vitro.
- No significant cytotoxicity was observed at effective concentrations.
Conclusions:
- MitoCDNB represents the first compound shown to inhibit platelet activation via targeting mitochondrial TrxR2 and respiration.
- This novel mitochondria-targeting strategy offers a new therapeutic avenue for antiplatelet therapy.
- Further development of MitoCDNB could lead to antiplatelet drugs with minimized systemic risks.
More Related Videos
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
01:30The Electron Transport Chain
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
01:45Mitochondrial Membranes
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:19Translocation of Proteins into the Mitochondria
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...